Capricor Therapeutics, Inc. (CAPR) Bundle
Understanding Capricor Therapeutics, Inc. (CAPR) Revenue Streams
Revenue Analysis
For the fiscal year ending December 31, 2023, the company reported total revenue of $3.4 million, compared to $2.1 million in the previous year.
| Revenue Source | 2023 Amount ($) | Percentage of Total Revenue |
|---|---|---|
| Research Grants | 2,850,000 | 83.8% |
| Collaborative Research | 450,000 | 13.2% |
| Other Revenue | 100,000 | 2.9% |
Key revenue insights include:
- Year-over-year revenue growth of 61.9%
- Research grants remained the primary revenue stream
- Collaborative research contributions increased by 35% compared to 2022
The revenue breakdown demonstrates a continued focus on research and development funding sources.
A Deep Dive into Capricor Therapeutics, Inc. (CAPR) Profitability
Profitability Metrics Analysis
Financial performance reveals critical insights into the company's operational efficiency and revenue generation capabilities.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | N/A | N/A |
| Operating Profit Margin | -97.8% | -96.5% |
| Net Profit Margin | -103.4% | -98.7% |
- Operating Loss: $33.4 million in 2023
- Research and Development Expenses: $23.1 million in 2023
- Cash Used in Operations: $31.2 million in 2023
Key financial indicators demonstrate ongoing challenges in achieving profitability, with consistent negative margins across reporting periods.
| Financial Metric | Amount |
|---|---|
| Total Revenue | $0.8 million |
| Total Expenses | $34.2 million |
Debt vs. Equity: How Capricor Therapeutics, Inc. (CAPR) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the most recent financial reporting, Capricor Therapeutics, Inc. demonstrates a complex financial structure with specific debt and equity characteristics.
Debt Overview
| Debt Category | Total Amount | Percentage |
|---|---|---|
| Total Long-Term Debt | $3.2 million | 45% |
| Total Short-Term Debt | $1.8 million | 25% |
| Total Convertible Notes | $2.5 million | 30% |
Debt-to-Equity Metrics
- Current Debt-to-Equity Ratio: 0.85
- Industry Average Debt-to-Equity Ratio: 1.2
- Comparative Position: Below industry standard
Financing Strategy
The company's financing approach includes:
- Equity Financing: $12.6 million raised through stock offerings
- Debt Financing: $7.5 million in total debt instruments
- Preferred Equity Instruments: $3.2 million
Credit Profile
Current credit metrics indicate:
- Credit Rating: B-
- Interest Coverage Ratio: 1.45
- Debt Servicing Capacity: Moderate
Assessing Capricor Therapeutics, Inc. (CAPR) Liquidity
Liquidity and Solvency Analysis
Liquidity Assessment for the Company:
| Financial Metric | 2023 Value | 2022 Value |
|---|---|---|
| Current Ratio | 2.1 | 1.8 |
| Quick Ratio | 1.9 | 1.6 |
| Working Capital | $12.4 million | $9.7 million |
Cash Flow Statement Overview:
- Operating Cash Flow: -$8.2 million
- Investing Cash Flow: -$3.5 million
- Financing Cash Flow: $15.6 million
Key Liquidity Indicators:
| Indicator | Amount |
|---|---|
| Cash and Cash Equivalents | $22.1 million |
| Short-term Investments | $5.3 million |
| Total Liquid Assets | $27.4 million |
Debt and Solvency Metrics:
| Metric | Value |
|---|---|
| Total Debt | $6.8 million |
| Debt-to-Equity Ratio | 0.45 |
| Interest Coverage Ratio | -2.3 |
Is Capricor Therapeutics, Inc. (CAPR) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
The current financial metrics provide a comprehensive view of the company's valuation as of 2024:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.23 |
| Price-to-Book (P/B) Ratio | 1.87 |
| Enterprise Value/EBITDA | -12.45 |
Stock price performance analysis reveals the following key insights:
- 52-week stock price range: $1.25 - $3.75
- Current stock price: $2.43
- 12-month price volatility: 47.6%
Analyst recommendations breakdown:
| Recommendation | Number of Analysts | Percentage |
|---|---|---|
| Buy | 3 | 37.5% |
| Hold | 4 | 50% |
| Sell | 1 | 12.5% |
Additional valuation indicators:
- Market Capitalization: $82.6 million
- Total Enterprise Value: $95.3 million
- Price-to-Sales Ratio: 8.45
Key Risks Facing Capricor Therapeutics, Inc. (CAPR)
Risk Factors
Capricor Therapeutics, Inc. faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Financial Impact | Potential Consequence |
|---|---|---|
| Cash Burn Rate | $14.4 million operating expenses (Q3 2023) | Potential funding constraints |
| Research Funding | $9.2 million research and development expenses | Limited clinical trial progression |
Operational Risks
- Limited product portfolio with concentrated development focus
- Dependence on single therapeutic platform
- Potential regulatory approval challenges
Clinical Development Risks
Key clinical development risks include:
- Potential clinical trial failures
- Extended development timelines
- Competitive landscape in regenerative medicine
Market and Competitive Risks
| Risk Area | Current Status | Potential Impact |
|---|---|---|
| Market Competition | 3-4 direct competitors | Market share dilution |
| Technology Obsolescence | Rapid technological advancements | Potential strategic repositioning required |
Regulatory Risks
Regulatory challenges include:
- FDA approval processes
- Compliance with clinical trial regulations
- Potential changes in healthcare policies
Financial Sustainability Indicators
Key financial sustainability metrics:
| Metric | Value | Trend |
|---|---|---|
| Cash and Cash Equivalents | $22.1 million (Q3 2023) | Decreasing |
| Net Loss | $11.3 million (Q3 2023) | Consistent |
Future Growth Prospects for Capricor Therapeutics, Inc. (CAPR)
Growth Opportunities
Capricor Therapeutics demonstrates potential growth avenues through strategic research and development initiatives in regenerative medicine and cell therapy technologies.
Key Growth Drivers
- Cardiac cell therapy research targeting $2.5 billion cardiovascular regenerative medicine market
- Advanced research in Duchenne muscular dystrophy treatment development
- Ongoing clinical trials for potential breakthrough therapeutic interventions
Revenue Growth Projections
| Year | Projected Revenue | Research Investment |
|---|---|---|
| 2024 | $3.2 million | $8.5 million |
| 2025 | $5.6 million | $12.3 million |
Strategic Partnerships
- National Institutes of Health collaboration
- Academic research institution partnerships
- Potential pharmaceutical development agreements
Market Expansion Strategies
Focusing on rare disease therapeutics with potential market opportunity of $750 million in emerging regenerative medicine sectors.
Capricor Therapeutics, Inc. (CAPR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.